President Biden signed the Inflation Reduction Act (IRA) into law on August 16th. The law includes new spending on climate initiatives, new taxes and enforcement, and drug pricing controls include significant changes to the Medicare Part D benefit. On the surface, measures to address drug pricing has had broad bipartisan support; however, the implications from this law may have unintended consequences to the Part D beneficiaries, payers, as well as to drug development and innovation for years.
Explore the increasing level of influence IDNs have over drug therapy prescribing and what tools they are leveraging to manage drug costs and spend.
Stay up to date on the implications of President Biden’s new Build Back Better Act (BBBA). Ryan Cox takes us through the act's provisions to address drug spending by the federal government and private payers, as well as the impact on Medicare Drug Access.
Stay up-to-date as Ryan Cox discusses how accumulators and maximizers are being used by PBMs and health plans in response to continued pressure between plan benefit design, the expansion of manufacturer copay programs, and the growth of drug spending.
With Joe Biden’s inauguration as the 46th president of the United States and Democrat control of both the house and senate, there are a number of policy changes anticipated. As expected, the current focus of the administration is the pandemic, bolstering the roll-out of the vaccine and providing economic support to those parts of the economy that have been most impacted, but what else? Precision’s Ryan Cox explores some of the expected policy priorities and changes for healthcare in 2021.
Almost to the level of saturation, there have been a remarkably high number of articles and publications examining the impact of COVID-19 on the US healthcare system. Precision’s Ryan Cox takes a look at some of the less-mentioned trends hinting at changes coming to health systems in the near future.
Team members Ryan Cox and Erin Lopata examine consolidation among health systems. Will this trend lead to lower costs and better care or should stakeholders be more concerned with the growing power of the industry heavyweights?
Ryan Cox outlines the recent efforts of his previous employer, Highmark BCBS, and their creation of the Highmark Cancer Collective to promote evidence-based treatment pathways.